113 related articles for article (PubMed ID: 35554932)
21. Second cancers and late mortality in Australian children treated by allogeneic HSCT for haematological malignancy.
Nelson AS; Ashton LJ; Vajdic CM; Le Marsney RE; Daniels B; Nivison-Smith I; Wilcox L; Dodds AJ; O'Brien TA;
Leukemia; 2015 Feb; 29(2):441-7. PubMed ID: 24962016
[TBL] [Abstract][Full Text] [Related]
22. Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience.
Busca A; Cinatti N; Gill J; Passera R; Dellacasa CM; Giaccone L; Dogliotti I; Manetta S; Corcione S; De Rosa FG
Front Cell Infect Microbiol; 2021; 11():805514. PubMed ID: 35071052
[TBL] [Abstract][Full Text] [Related]
23. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
[TBL] [Abstract][Full Text] [Related]
24. Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study.
Teng CJ; Hu YW; Chen SC; Yeh CM; Chiang HL; Chen TJ; Liu CJ
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26538627
[TBL] [Abstract][Full Text] [Related]
25. Second Cancer Risk and Late Mortality in Adult Australians Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Population-Based Cohort Study.
Vajdic CM; Mayson E; Dodds AJ; O'Brien T; Wilcox L; Nivison-Smith I; Le Marsney R; Daniels B; Ashton LJ;
Biol Blood Marrow Transplant; 2016 May; 22(5):949-56. PubMed ID: 26860637
[TBL] [Abstract][Full Text] [Related]
26. Risk factors for acute kidney injury in patients undergoing allogeneic hematopoietic stem cell transplantation.
Yu ZP; Ding JH; Chen BA; Liu BC; Liu H; Li YF; Ding BH; Qian J
Chin J Cancer; 2010 Nov; 29(11):946-51. PubMed ID: 20979694
[TBL] [Abstract][Full Text] [Related]
27. Increased risk of gastrointestinal malignancy in patients with diabetes mellitus and correlations with anti-diabetes drugs: a nationwide population-based study in Taiwan.
Chiu CC; Huang CC; Chen YC; Chen TJ; Liang Y; Lin SJ; Chen JW; Leu HB; Chan WL
Intern Med; 2013; 52(9):939-46. PubMed ID: 23648711
[TBL] [Abstract][Full Text] [Related]
28. Risk Factors for and the Prognostic Impact of Pericardial Effusion after Allogeneic Hematopoietic Stem Cell Transplantation.
Kubo H; Imataki O; Fukumoto T; Oku M; Ishida T; Kubo YH; Kida JI; Uemura M; Fujita H; Ohno H; Ide M; Ohnishi H; Kadowaki N
Transplant Cell Ther; 2021 Nov; 27(11):949.e1-949.e8. PubMed ID: 34333179
[TBL] [Abstract][Full Text] [Related]
29. Outcome and late effects among acute myeloid leukemia survivors: a nationwide population-based study.
Chang KH; Hwang WL; Muo CH; Hsu CY; Teng CJ
Support Care Cancer; 2016 Dec; 24(12):4993-5000. PubMed ID: 27502072
[TBL] [Abstract][Full Text] [Related]
30. Predictive implications of albumin and C-reactive protein for progression to pneumonia and poor prognosis in Stenotrophomonas maltophilia bacteremia following allogeneic hematopoietic stem cell transplantation.
Harada K; Sekiya N; Konishi T; Nagata A; Yamada Y; Takezaki T; Kaito S; Kurosawa S; Sakaguchi M; Yasuda S; Sasaki S; Yoshioka K; Watakabe-Inamoto K; Igarashi A; Najima Y; Hagino T; Muto H; Kobayashi T; Doki N; Kakihana K; Sakamaki H; Ohashi K
BMC Infect Dis; 2017 Sep; 17(1):638. PubMed ID: 28938875
[TBL] [Abstract][Full Text] [Related]
31. Trends in Late Mortality and Life Expectancy After Allogeneic Blood or Marrow Transplantation Over 4 Decades: A Blood or Marrow Transplant Survivor Study Report.
Bhatia S; Dai C; Landier W; Hageman L; Wu J; Schlichting E; Siler A; Funk E; Hicks J; Bosworth A; Te HS; Francisco L; Bhatia R; Salzman D; Goldman FD; Forman SJ; Weisdorf DJ; Wong FL; Arora M; Armenian SH
JAMA Oncol; 2021 Nov; 7(11):1626-1634. PubMed ID: 34499078
[TBL] [Abstract][Full Text] [Related]
32. Late Complications and Quality of Life after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation.
Clavert A; Peric Z; Brissot E; Malard F; Guillaume T; Delaunay J; Dubruille V; Le Gouill S; Mahe B; Gastinne T; Blin N; Harousseau JL; Moreau P; Milpied N; Mohty M; Chevallier P
Biol Blood Marrow Transplant; 2017 Jan; 23(1):140-146. PubMed ID: 27751934
[TBL] [Abstract][Full Text] [Related]
33. Discontinuation and Nonadherence to Medications for Chronic Conditions after Hematopoietic Cell Transplantation: A 6-Year Propensity Score-Matched Cohort Study.
Zhou J; Han J; Nutescu EA; Patel PR; Sweiss K; Calip GS
Pharmacotherapy; 2019 Jan; 39(1):55-66. PubMed ID: 30485471
[TBL] [Abstract][Full Text] [Related]
34. Programmed death 1 ligand (PD-L1) in solid cancers after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Nagasaki Transplant Group.
Kasai S; Itonaga H; Niino D; Miyoshi H; Kato T; Imanishi D; Fujioka M; Furumoto T; Sato S; Sawayama Y; Taguchi J; Imaizumi Y; Hata T; Yoshida S; Moriuchi Y; Ohshima K; Miyazaki Y
Int J Hematol; 2020 Oct; 112(4):524-534. PubMed ID: 32588395
[TBL] [Abstract][Full Text] [Related]
35. Universal Engraftment after Allogeneic Hematopoietic Cell Transplantation Using Cryopreserved CD34-Selected Grafts.
Jacob RP; Flynn J; Devlin SM; Maloy M; Giralt SA; Maslak P; O'Reilly RJ; Tonon JA; Perales MA; Avecilla ST; Cho C
Transplant Cell Ther; 2021 Aug; 27(8):697.e1-697.e5. PubMed ID: 33991721
[TBL] [Abstract][Full Text] [Related]
36. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning.
Majhail NS; Brazauskas R; Rizzo JD; Sobecks RM; Wang Z; Horowitz MM; Bolwell B; Wingard JR; Socie G
Blood; 2011 Jan; 117(1):316-22. PubMed ID: 20926773
[TBL] [Abstract][Full Text] [Related]
37. Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2020 Aug; 99(8):1883-1893. PubMed ID: 32572523
[TBL] [Abstract][Full Text] [Related]
38. Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC.
Chevallier P; Labopin M; Socie G; Rubio MT; Blaise D; Vigouroux S; Huynh A; Michallet M; Bay JO; Maury S; Yakoub-Agha I; Fegueux N; Deconinck E; Contentin N; Maillard N; Bulabois CE; Francois S; Oumedaly R; Raus N; Mohty M
Eur J Haematol; 2015 May; 94(5):449-55. PubMed ID: 25238651
[TBL] [Abstract][Full Text] [Related]
39. Incidence, etiology, risk factors, and outcomes of pre-engraftment bloodstream infections after first and second allogeneic hematopoietic cell transplantation.
Akhmedov M; Klyasova G; Kuzmina L; Fedorova A; Vasilyeva V; Drokov M; Parovichnikova E
Transpl Infect Dis; 2022 Jun; 24(3):e13842. PubMed ID: 35501664
[TBL] [Abstract][Full Text] [Related]
40. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
